» Articles » PMID: 39866301

Profiles of Systemic Lupus Erythematosus Patients with Co-existing Sickle Cell Disease: a Coincidence or True Association?

Overview
Journal Reumatologia
Publisher Termedia
Date 2025 Jan 27
PMID 39866301
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Systemic lupus erythematosus (SLE) and sickle cell disease (SCD) are distinct multisystemic diseases that commonly affect blacks. There are few reports of their co-existence in Western literature and a paucity of reports in Sub-Saharan Africa. Their co-existence is associated with diagnostic delay and treatment dilemmas. The aim is to describe the clinical, laboratory, and treatment profile of Nigerian lupus with sickle cell disease.

Material And Methods: A 7-year retrospective descriptive study of lupus patients with sickle cell disease was performed. Medical records of eligible patients were extracted into a proforma, transferred into SPSS, and analyzed with descriptive statistics. Sociodemographic, clinical, laboratory, and treatment data were presented as frequency and percentages.

Results: Twelve SLE-SCD cases (female 11, male 1) were identified. The mean age was 28.5 years and the mean duration of illness prior to diagnosis was 9.5 years. The median follow-up period was 3.1 years and the common presentations were mucocutaneous (66%), renal, (50%) serositis (33%), and neurological (16%) in decreasing order. All had anemia and positive antinuclear antibody, 33% had pancytopenia and 75% had positive anti-dsDNA and anti-Smith. Two are on maintenance hemodialysis, one with interstitial lung disease, and one on long-term anticoagulation due to deep vein thrombosis.

Conclusions: Sickle cell disease and SLE should be considered in SCD with atypical clinical and laboratory features. We hope this report will raise diagnostic suspicion and prompt early diagnosis and treatment to prevent multiorgan damage that may ensue from such an association.

References
1.
Toly-Ndour C, Rouquette A, Obadia S, MBappe P, Lionnet F, Hagege I . High titers of autoantibodies in patients with sickle-cell disease. J Rheumatol. 2010; 38(2):302-9. DOI: 10.3899/jrheum.100667. View

2.
. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023; 10(8):e585-e599. PMC: 10390339. DOI: 10.1016/S2352-3026(23)00118-7. View

3.
Schiliro D, Silvagni E, Ciribe B, Fattorini F, Maccarrone V, Elefante E . Systemic lupus erythematosus: one year in review 2024. Clin Exp Rheumatol. 2024; 42(3):583-592. DOI: 10.55563/clinexprheumatol/mnvmvo. View

4.
. Global, regional, and national burden of other musculoskeletal disorders, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023; 5(11):e670-e682. PMC: 10620749. DOI: 10.1016/S2665-9913(23)00232-1. View

5.
Merashli M, Arcaro A, Graf M, Caruso M, Ames P, Gentile F . Antiphospholipid Antibodies in Sickle Cell Disease: A Systematic Review and Exploratory Meta-Analysis. Clin Appl Thromb Hemost. 2021; 27:10760296211002914. PMC: 8020102. DOI: 10.1177/10760296211002914. View